Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Correction to: The 2018 UK NHS Digital annual report on the Improving Access to Psychological Therapies programme: a brief commentary.

Moller NP, Ryan G, Rollings J, Barkham M.

BMC Psychiatry. 2019 Oct 17;19(1):302. doi: 10.1186/s12888-019-2277-2.

2.

Who Attends Couples Counseling in the UK and Why?

Duncan C, Ryan G, Moller NP, Davies R.

J Sex Marital Ther. 2019 Sep 9:1-10. doi: 10.1080/0092623X.2019.1654584. [Epub ahead of print]

PMID:
31496384
3.

The 2018 UK NHS Digital annual report on the Improving Access to Psychological Therapies programme: a brief commentary.

Moller NP, Ryan G, Rollings J, Barkham M.

BMC Psychiatry. 2019 Aug 14;19(1):252. doi: 10.1186/s12888-019-2235-z. Erratum in: BMC Psychiatry. 2019 Oct 17;19(1):302.

5.

'Eating disorders are not about food, they're about life': Client perspectives on anorexia nervosa treatment.

Rance N, Moller NP, Clarke V.

J Health Psychol. 2017 Apr;22(5):582-594. doi: 10.1177/1359105315609088. Epub 2015 Oct 7.

PMID:
26446375
6.

Defining infidelity in research and couple counseling: a qualitative study.

Moller NP, Vossler A.

J Sex Marital Ther. 2015;41(5):487-97. doi: 10.1080/0092623X.2014.931314. Epub 2014 Aug 25.

PMID:
24918514
7.

"If I see somebody…I'll immediately scope them out": anorexia nervosa clients' perceptions of their therapists' body.

Rance NM, Clarke V, Moller NP.

Eat Disord. 2014;22(2):111-20. doi: 10.1080/10640266.2013.860847. Epub 2013 Dec 10.

PMID:
24555509
8.

Eating disorder counsellors with eating disorder histories: a story of being "normal".

Rance NM, Moller NP, Douglas BA.

Eat Disord. 2010 Oct-Dec;18(5):377-92. doi: 10.1080/10640266.2010.511901.

PMID:
20865592
9.

Lipase inhibitory activity in alcohol extracts of worldwide occurring plants and propolis.

Möller NP, Roos N, Schrezenmeir J.

Phytother Res. 2009 Apr;23(4):585-6. doi: 10.1002/ptr.2637.

PMID:
19003950
10.

Bioactive peptides and proteins from foods: indication for health effects.

Möller NP, Scholz-Ahrens KE, Roos N, Schrezenmeir J.

Eur J Nutr. 2008 Jun;47(4):171-82. doi: 10.1007/s00394-008-0710-2. Epub 2008 May 27. Review.

PMID:
18506385
11.

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.

Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP, Skak K, Lundsgaard D, Frederiksen KS, Thygesen P, McArthur GA.

Clin Cancer Res. 2007 Jun 15;13(12):3630-6.

12.

Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling.

Lund IK, Hansen JA, Andersen HS, Møller NP, Billestrup N.

J Mol Endocrinol. 2005 Apr;34(2):339-51.

PMID:
15821101
13.

Residue 259 in protein-tyrosine phosphatase PTP1B and PTPalpha determines the flexibility of glutamine 262.

Peters GH, Iversen LF, Andersen HS, Møller NP, Olsen OH.

Biochemistry. 2004 Jul 6;43(26):8418-28.

PMID:
15222753
14.

Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta.

Lund IK, Andersen HS, Iversen LF, Olsen OH, Møller KB, Pedersen AK, Ge Y, Holsworth DD, Newman MJ, Axe FU, Møller NP.

J Biol Chem. 2004 Jun 4;279(23):24226-35. Epub 2004 Mar 15.

15.

A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage.

Andersen JN, Jansen PG, Echwald SM, Mortensen OH, Fukada T, Del Vecchio R, Tonks NK, Møller NP.

FASEB J. 2004 Jan;18(1):8-30. Review.

PMID:
14718383
16.

Affinity purification of recombinant protein-tyrosine phosphatase 1B using a highly selective inhibitor.

Pedersen AK, Branner S, Mortensen SB, Andersen HS, Klausen KM, Møller KB, Møller NP, Iversen LF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):1-8.

PMID:
14659430
17.

Cellular effects of small molecule PTP1B inhibitors on insulin signaling.

Xie L, Lee SY, Andersen JN, Waters S, Shen K, Guo XL, Moller NP, Olefsky JM, Lawrence DS, Zhang ZY.

Biochemistry. 2003 Nov 11;42(44):12792-804.

PMID:
14596593
18.

Residue 182 influences the second step of protein-tyrosine phosphatase-mediated catalysis.

Pedersen AK, Guo XL, Møller KB, Peters GH, Andersen HS, Kastrup JS, Mortensen SB, Iversen LF, Zhang ZY, Møller NP.

Biochem J. 2004 Mar 1;378(Pt 2):421-33.

19.

Enzyme kinetic characterization of protein tyrosine phosphatases.

Peters GH, Branner S, Møller KB, Andersen JN, Møller NP.

Biochimie. 2003 May;85(5):527-34.

PMID:
12763312
21.

Ligand-induced conformational changes: improved predictions of ligand binding conformations and affinities.

Frimurer TM, Peters GH, Iversen LF, Andersen HS, Møller NP, Olsen OH.

Biophys J. 2003 Apr;84(4):2273-81.

22.

Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B.

Andersen HS, Olsen OH, Iversen LF, Sørensen AL, Mortensen SB, Christensen MS, Branner S, Hansen TK, Lau JF, Jeppesen L, Moran EJ, Su J, Bakir F, Judge L, Shahbaz M, Collins T, Vo T, Newman MJ, Ripka WC, Møller NP.

J Med Chem. 2002 Sep 26;45(20):4443-59.

PMID:
12238924
23.

Paper-and-pencil or online? Evaluating mode effects on measures of emotional functioning and attachment.

Fouladi RT, McCarthy CJ, Moller NP.

Assessment. 2002 Jun;9(2):204-15.

PMID:
12066835
24.

Structure determination of T cell protein-tyrosine phosphatase.

Iversen LF, Moller KB, Pedersen AK, Peters GH, Petersen AS, Andersen HS, Branner S, Mortensen SB, Moller NP.

J Biol Chem. 2002 May 31;277(22):19982-90. Epub 2002 Mar 20.

25.

Structural and evolutionary relationships among protein tyrosine phosphatase domains.

Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, Jansen PG, Andersen HS, Tonks NK, Møller NP.

Mol Cell Biol. 2001 Nov;21(21):7117-36. Review. No abstract available.

26.

Comparative study of protein tyrosine phosphatase-epsilon isoforms: membrane localization confers specificity in cellular signalling.

Andersen JN, Elson A, Lammers R, Rømer J, Clausen JT, Møller KB, Møller NP.

Biochem J. 2001 Mar 15;354(Pt 3):581-90.

27.

Protein tyrosine phosphatases (PTPs) as drug targets: inhibitors of PTP-1B for the treatment of diabetes.

Møller NP, Iversen LF, Andersen HS, McCormack JG.

Curr Opin Drug Discov Devel. 2000 Sep;3(5):527-40.

PMID:
19649881
28.

Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and alpha.

Peters GH, Iversen LF, Branner S, Andersen HS, Mortensen SB, Olsen OH, Moller KB, Moller NP.

J Biol Chem. 2000 Jun 16;275(24):18201-9.

29.

Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B.

Iversen LF, Andersen HS, Branner S, Mortensen SB, Peters GH, Norris K, Olsen OH, Jeppesen CB, Lundt BF, Ripka W, Møller KB, Møller NP.

J Biol Chem. 2000 Apr 7;275(14):10300-7.

30.

2-(oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases.

Andersen HS, Iversen LF, Jeppesen CB, Branner S, Norris K, Rasmussen HB, Møller KB, Møller NP.

J Biol Chem. 2000 Mar 10;275(10):7101-8.

31.

Protein-tyrosine phosphatase alpha regulates Src family kinases and alters cell-substratum adhesion.

Harder KW, Moller NP, Peacock JW, Jirik FR.

J Biol Chem. 1998 Nov 27;273(48):31890-900.

32.

Mutant forms of the protein tyrosine phosphatase alpha show differential activities towards intracellular substrates.

Lammers R, Møller NP, Ullrich A.

Biochem Biophys Res Commun. 1998 Jan 6;242(1):32-8.

PMID:
9439605
33.

Expression of protein-tyrosine phosphatases in the major insulin target tissues.

Norris K, Norris F, Kono DH, Vestergaard H, Pedersen O, Theofilopoulos AN, Møller NP.

FEBS Lett. 1997 Oct 6;415(3):243-8.

34.
35.

ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation.

Lechner C, Zahalka MA, Giot JF, Møller NP, Ullrich A.

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4355-9.

36.

Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphatases alpha and epsilon.

Møller NP, Møller KB, Lammers R, Kharitonenkov A, Hoppe E, Wiberg FC, Sures I, Ullrich A.

J Biol Chem. 1995 Sep 29;270(39):23126-31.

37.

Src kinase associates with a member of a distinct subfamily of protein-tyrosine phosphatases containing an ezrin-like domain.

Møller NP, Møller KB, Lammers R, Kharitonenkov A, Sures I, Ullrich A.

Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7477-81.

38.

Expression, purification and crystallization of human phosphotyrosine phosphatase 1B.

Hoppe E, Berne PF, Stock D, Rasmussen JS, Møller NP, Ullrich A, Huber R.

Eur J Biochem. 1994 Aug 1;223(3):1069-77.

39.

Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA.

Kristensen T, Oxvig C, Sand O, Møller NP, Sottrup-Jensen L.

Biochemistry. 1994 Feb 15;33(6):1592-8.

PMID:
7508748
40.

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NP, Risau W, Ullrich A.

Cell. 1993 Mar 26;72(6):835-46.

PMID:
7681362
41.

Identification of determinants that confer ligand specificity on the insulin receptor.

Andersen AS, Kjeldsen T, Wiberg FC, Vissing H, Schäffer L, Rasmussen JS, De Meyts P, Møller NP.

J Biol Chem. 1992 Jul 5;267(19):13681-6.

42.

Molecular cloning and mammalian expression of human beta 2-glycoprotein I cDNA.

Kristensen T, Schousboe I, Boel E, Mulvihill EM, Hansen RR, Møller KB, Møller NP, Sottrup-Jensen L.

FEBS Lett. 1991 Sep 9;289(2):183-6.

43.

The ligand specificities of the insulin receptor and the insulin-like growth factor I receptor reside in different regions of a common binding site.

Kjeldsen T, Andersen AS, Wiberg FC, Rasmussen JS, Schäffer L, Balschmidt P, Møller KB, Møller NP.

Proc Natl Acad Sci U S A. 1991 May 15;88(10):4404-8.

44.

Changing the insulin receptor to possess insulin-like growth factor I ligand specificity.

Andersen AS, Kjeldsen T, Wiberg FC, Christensen PM, Rasmussen JS, Norris K, Møller KB, Møller NP.

Biochemistry. 1990 Aug 14;29(32):7363-6.

PMID:
2223767
45.

Analysis of the decreased NK (natural killer) activity in lung cancer patients, using whole blood versus separated mononuclear cells.

Nielsen LR, Kimose HH, Linnet L, Møller NP, Bukh A.

J Clin Lab Immunol. 1989 Jun;29(2):71-7.

PMID:
2632804
46.
47.

A polyclonal IgM-RF enzyme-linked immunosorbent assay for the detection of circulating immune complexes.

Bukh A, Thomsen BS, Kimose HH, Nielsen LR, Svehag SE, Møller NP.

J Clin Lab Immunol. 1988 Aug;26(4):195-200.

PMID:
3199429
48.

Applications of immunoperoxidase techniques in specificity testing of monoclonal antibodies (Mabs) against von Willebrand factor (vWf).

Ingerslev J, Bukh A, Møller NP, Stenbjerg S, Zeuthen J.

Clin Chim Acta. 1988 May 13;174(1):65-81.

PMID:
3260153
49.

A prospective study of circulating immune complexes in patients with breast cancer.

Bukh A, Aguado MT, Krarup N, Poulsen HS, Nordentoft AM, Møller NP.

Int J Cancer. 1988 Mar 15;41(3):364-70.

PMID:
3257943
50.

Prognostic value of serial determinations of circulating immune complex levels in malignant melanoma.

Bukh A, Møller-Larsen A, Aguado MT, Møller-Larsen F, Møller NP.

Cancer Immunol Immunother. 1988;26(3):280-4.

PMID:
3260134

Supplemental Content

Loading ...
Support Center